GPCR

Basketball players hands reaching for a ball near the hoop during a professional game
Biotech

Exicure scores in phase 2 multiple myeloma program

Since market open, Exicure’s stock has shot up 65%, rising from Friday’s close of $5.27 per share to $8.73 as of 10:10 a.m. ET today.
Gabrielle Masson Dec 9, 2025 10:15am
Dollar sign on digital background

Lilly pens $1.3B pact with Superluminal to work on GPCR drugs

Aug 14, 2025 9:45am
finance numbers tape money

Novo Nordisk inks $812M Deep Apple deal to pursue obesity target

Jun 11, 2025 7:00am
graphic image of different colored hands shaking

Sotio takes up option on ADCs, Boehringer inks discovery pact

Mar 13, 2025 10:53am
Three blocks displaying from left to right a person a handshake and another person

Exicure buys GPCR's US unit and clinical-stage blood cancer drug

Jan 23, 2025 5:01am
IPO initial public offering

Septerna goes public with upsized offering of $288M

Oct 25, 2024 10:29am